SINGAPORE (May 2): HealthBaby Biotech (Hong Kong), a wholly-owned subsidiary of Cordlife Group, has launched a newborn metabolic screening service in Hong Kong.
This comes as part of Cordlife’s move to expand its diagnostics business, the group said in a Wednesday press release.
Named Metascreen, the service uses urine instead of blood to detect over 100 inherited metabolic disorders — which is much more than what can be detected by conventional newborn metabolic screening tests currently...(click on link for full story on theedgesingapore.com)